## Prakash Narayan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5749166/publications.pdf

Version: 2024-02-01

		1478505	1125743	
15	156	6	13	
papers	citations	h-index	g-index	
15	15	15	213	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Collagen Characterization in a Model of Nonalcoholic Steatohepatitis with Fibrosis; A Call for Development of Targeted Therapeutics. Molecules, 2021, 26, 3316.	3.8	8
2	Hepatic mRNA Expression Levels of the Oncogenes Alpha-Fetoprotein and Osteopontin as Diagnostics for Liver Cancer in a Murine Model of Diet-Induced Non-Alcoholic Steatohepatitis. Processes, 2021, 9, 1516.	2.8	0
3	Identification of Disease-associated MicroRNA in a Diet-induced Model of Nonalcoholic Steatohepatitis. Molecular Omics, 2021, 17, 911-916.	2.8	0
4	Liver Biopsy Hydroxyproline Content Is a Diagnostic for Hepatocellular Carcinoma in Murine Models of Nonalcoholic Steatohepatitis. Diagnostics, 2020, 10, 784.	2.6	6
5	Glycerol-3-phosphate Acyltransferase1 Is a Model-Agnostic Node in Nonalcoholic Fatty Liver Disease: Implications for Drug Development and Precision Medicine. ACS Omega, 2020, 5, 18465-18471.	3.5	6
6	An Improved Method for Estimating Renal Dimensions; Implications for Management of Kidney Disease. Applied Sciences (Switzerland), 2019, 9, 3198.	2.5	3
7	Remodeling of Intrahepatic Ducts in a Model of Caroli Syndrome: Is Scar Carcinoma a Consequence of Laplace's Law?. Medical Sciences (Basel, Switzerland), 2019, 7, 55.	2.9	1
8	A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease. World Journal of Nephrology, 2018, 7, 96-107.	2.0	2
9	Deep Learning in Drug Discovery and Medicine; Scratching the Surface. Molecules, 2018, 23, 2384.	3.8	69
10	Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH. PLoS ONE, 2018, 13, e0198937.	2.5	16
11	A modified elliptical formula to estimate kidney collagen content in a model of chronic kidney disease. PLoS ONE, 2018, 13, e0190815.	2.5	4
12	Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World Journal of Gastroenterology, 2017, 23, 4181.	3.3	14
13	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. American Journal of Physiology - Renal Physiology, 2016, 311, F352-F361.	2.7	15
14	An Empirical Biomarker-Based Calculator for Cystic Index in a Model of Autosomal Recessive Polycystic Kidney Diseaseâ€"The Nieto-Narayan Formula. PLoS ONE, 2016, 11, e0163063.	2.5	8
15	A Biomarker Cluster for Polycystic Kidney Disease: Correlation with Cystic Index. Recent Patents on Biomarkers, 2015, 5, 35-43.	0.2	4